Antibiotics Need Additional Development Incentives, FDA Says
Executive Summary
Government incentives likely will be necessary to rejuvenate the development pipeline for antibiotics, Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, told a congressional committee
You may also be interested in...
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.